Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer
Significant ethnic differences in susceptibility to the effects of chemotherapy exist. Here, we retrospectively analyzed the safety and efficacy of induction chemotherapy (ICT) with dose-modified docetaxel, cisplatin, and 5-fluorouracil (TPF) in Asian patients with borderline resectable or unresecta...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664616300158 |
_version_ | 1811317644302745600 |
---|---|
author | Hung-Ming Wang Chien-Yu Lin Chia-Hsun Hsieh Cheng-Lung Hsu Kang-Hsing Fan Joseph Tung-Chieh Chang Shiang-Fu Huang Chung-Jan Kang Chun-Ta Liao Shu-Hang Ng Tzu-Chen Yen |
author_facet | Hung-Ming Wang Chien-Yu Lin Chia-Hsun Hsieh Cheng-Lung Hsu Kang-Hsing Fan Joseph Tung-Chieh Chang Shiang-Fu Huang Chung-Jan Kang Chun-Ta Liao Shu-Hang Ng Tzu-Chen Yen |
author_sort | Hung-Ming Wang |
collection | DOAJ |
description | Significant ethnic differences in susceptibility to the effects of chemotherapy exist. Here, we retrospectively analyzed the safety and efficacy of induction chemotherapy (ICT) with dose-modified docetaxel, cisplatin, and 5-fluorouracil (TPF) in Asian patients with borderline resectable or unresectable head and neck squamous cell carcinoma (HNSCC).
Methods: Based on the incidence of adverse events that occurred during daily practice, TPF90 (90% of the original TPF dosage; docetaxel 67.5 mg/m2 on Day 1, cisplatin 67.5 mg/m2 on Day 1, and 5-fluorouracil 675 mg/m2 on Days 1–5) was used for HNSCC patients who were scheduled to receive ICT TPF.
Results: Between March 2011 and May 2014, 52 consecutive patients with borderline resectable or unresectable HNSCC were treated with ICT TPF90 followed by concurrent chemoradiotherapy. Forty-four patients (84.6%) received at least three cycles of ICT TPF90. The most commonly observed Grade 3–4 adverse events included neutropenia (35%), anemia (25%), stomatitis (35%), diarrhea (16%), and infections (13.5%). In an intention-to-treat analysis, the complete and partial response rates after ICT TPF90 were 13.5% and 59.6%, respectively. The complete and partial response rates following radiotherapy and salvage surgery were 42.3% and 25.0%, respectively. The estimated 3-year overall survival and progression-free survival rates were 41% [95% confidence interval (CI): 25–56%] and 23% (95% CI: 10–39%), respectively. The observed median overall survival and progression-free survival were 21.0 months (95% CI: 13.3–28.7 months) and 16.0 months (95% CI: 10.7–21.3 months), respectively.
Conclusion: TPF90 is a suitable option for Asian patients with borderline resectable or unresectable HNSCC who are scheduled for ICT. |
first_indexed | 2024-04-13T12:11:51Z |
format | Article |
id | doaj.art-ab1204153d834262ac0446f3de6abf3e |
institution | Directory Open Access Journal |
issn | 0929-6646 |
language | English |
last_indexed | 2024-04-13T12:11:51Z |
publishDate | 2017-03-01 |
publisher | Elsevier |
record_format | Article |
series | Journal of the Formosan Medical Association |
spelling | doaj.art-ab1204153d834262ac0446f3de6abf3e2022-12-22T02:47:28ZengElsevierJournal of the Formosan Medical Association0929-66462017-03-01116318519210.1016/j.jfma.2016.03.005Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancerHung-Ming Wang0Chien-Yu Lin1Chia-Hsun Hsieh2Cheng-Lung Hsu3Kang-Hsing Fan4Joseph Tung-Chieh Chang5Shiang-Fu Huang6Chung-Jan Kang7Chun-Ta Liao8Shu-Hang Ng9Tzu-Chen Yen10Division of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDepartment of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDivision of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDivision of Medical Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDepartment of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDepartment of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCSection of Head and Neck Surgery, Department of Otorhinolaryngology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCSection of Head and Neck Surgery, Department of Otorhinolaryngology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCSection of Head and Neck Surgery, Department of Otorhinolaryngology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDepartment of Diagnostic Radiology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCDepartment of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROCSignificant ethnic differences in susceptibility to the effects of chemotherapy exist. Here, we retrospectively analyzed the safety and efficacy of induction chemotherapy (ICT) with dose-modified docetaxel, cisplatin, and 5-fluorouracil (TPF) in Asian patients with borderline resectable or unresectable head and neck squamous cell carcinoma (HNSCC). Methods: Based on the incidence of adverse events that occurred during daily practice, TPF90 (90% of the original TPF dosage; docetaxel 67.5 mg/m2 on Day 1, cisplatin 67.5 mg/m2 on Day 1, and 5-fluorouracil 675 mg/m2 on Days 1–5) was used for HNSCC patients who were scheduled to receive ICT TPF. Results: Between March 2011 and May 2014, 52 consecutive patients with borderline resectable or unresectable HNSCC were treated with ICT TPF90 followed by concurrent chemoradiotherapy. Forty-four patients (84.6%) received at least three cycles of ICT TPF90. The most commonly observed Grade 3–4 adverse events included neutropenia (35%), anemia (25%), stomatitis (35%), diarrhea (16%), and infections (13.5%). In an intention-to-treat analysis, the complete and partial response rates after ICT TPF90 were 13.5% and 59.6%, respectively. The complete and partial response rates following radiotherapy and salvage surgery were 42.3% and 25.0%, respectively. The estimated 3-year overall survival and progression-free survival rates were 41% [95% confidence interval (CI): 25–56%] and 23% (95% CI: 10–39%), respectively. The observed median overall survival and progression-free survival were 21.0 months (95% CI: 13.3–28.7 months) and 16.0 months (95% CI: 10.7–21.3 months), respectively. Conclusion: TPF90 is a suitable option for Asian patients with borderline resectable or unresectable HNSCC who are scheduled for ICT.http://www.sciencedirect.com/science/article/pii/S0929664616300158Asiadocetaxelhead and neck cancerinduction chemotherapyresectability |
spellingShingle | Hung-Ming Wang Chien-Yu Lin Chia-Hsun Hsieh Cheng-Lung Hsu Kang-Hsing Fan Joseph Tung-Chieh Chang Shiang-Fu Huang Chung-Jan Kang Chun-Ta Liao Shu-Hang Ng Tzu-Chen Yen Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer Journal of the Formosan Medical Association Asia docetaxel head and neck cancer induction chemotherapy resectability |
title | Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer |
title_full | Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer |
title_fullStr | Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer |
title_full_unstemmed | Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer |
title_short | Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer |
title_sort | induction chemotherapy with dose modified docetaxel cisplatin and 5 fluorouracil in asian patients with borderline resectable or unresectable head and neck cancer |
topic | Asia docetaxel head and neck cancer induction chemotherapy resectability |
url | http://www.sciencedirect.com/science/article/pii/S0929664616300158 |
work_keys_str_mv | AT hungmingwang inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT chienyulin inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT chiahsunhsieh inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT chenglunghsu inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT kanghsingfan inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT josephtungchiehchang inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT shiangfuhuang inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT chungjankang inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT chuntaliao inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT shuhangng inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer AT tzuchenyen inductionchemotherapywithdosemodifieddocetaxelcisplatinand5fluorouracilinasianpatientswithborderlineresectableorunresectableheadandneckcancer |